Due to the PI's determination

It is a single-arm, open-label clinical study to assess the safety and efficacy of the C752 CAR-T Cells for patients with CD19+ refractory/relapsed B cell non-Hodgkin lymphoma.

Inclusion Criteria:

• Written informed consent in accordance with federal, local, and institutional guidelines, Males and females ≥18 years of age at the time of consent
• Documented diagnosis of Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
• Have progression by least one systemic treatment and no available standard of care treatment.
• At least one measurable lesion by Lugano 2014
• Expected survival ≥ 12 weeks
• Have an ECOG performance status of 0 or 1
• Adequate organ function
• Screening test indicates histopathological CD19 + if the subject received CD19-targeted therapy
• Women of childbearing age must have a negative pregnancy test, and agree to take effective contraception during the trial

Exclusion Criteria:

• Treatment with any prior HSCT, gene therapy product, cell therapy product ect.
• Central nervous system involvement
• HBV/HCV
• HIV infection
• Concurrent use of systemic steroids or immunosuppression
• Uncontrolled active infection
• Wash-out period of from the last anti-cancer treatment
• Active second malignancy
• Have not recovered from the effects of previous therapy
• Have psychological or physical conditions that do not permit compliance with the protocol
• Pregnant or nursing (lactating) women